Institutional Biosafety/recombinant DNA Committee (IBC) Charter
 
I. Introduction | II. Roles and Responsibilities | III. Research | IV. IBC Membership | V. IBC Policies and Procedures | VI. Protocol Review Process
 
Show as single page
VI. Protocol Review Process

  • After the Principal Investigator submits a protocol, the protocol form will be administratively checked by the IBC coordinator and forwarded to the IBC Chair and the BSO for an administrative screening.

  • Protocols will be reviewed and voted on at scheduled meetings of the IBC, if a quorum is present. A quorum for IBC meetings is defined as a majority of the voting members including at least one non-affiliated member of the committee. The IBC can, by majority vote, approve a protocol as is; approve a protocol conditionally; or table a protocol for modifications and further review. If a PI fails to address any concern by the IBC or fails to provide additional information requested by the IBC after three months from the request, then the IBC can take administrative action.

  • The IBC promotes compliance with the University policy regarding Conflicts of Interest (http://admin.utep.edu/Default.aspx?tabid=50599 ). IBC member(s) that serve as a Principal Investigator of a protocol that is being reviewed or has a personal or financial interest, must recuse themselves from the vote. This action will be recorded in the meeting minutes. Any protocols involving animals or human subjects will be shared between the IACUC and the IRB, and concurrent approvals will be required. All approved protocols will be active for three year terms and subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (see http://www4.od.nih.gov/oba/rDNA.htm). The Principal Investigator will be notified of the IBC’s decision via email with a formal memo for all protocols.

  • The PI must report immediately to the IBC any incidents involving contamination of personnel, research- related illnesses, accidental spills, loss of containment, and violations of the NIH Guidelines to the UTEP IBC Chair (915-747-8715) and BSO (915-747-7179) immediately and must reference the incident in the annual update. The IBC Chair and/or Vice-Chair in consultation with the BSO is responsible for reporting significant incidents, violations and research – related accidents and illnesses involving recombinant DNA to the IRO and the OBA within thirty (30) days or immediately depending on the nature of the incident.


V. IBC Policies and Procedures | Page 6 of 6 | VI. Protocol Review Process



   
News & Events

   
Links

The University of Texas at El Paso  |  Terms Of Use  |  Privacy Statement  |  Required Links